(Fig. 2) Recent advancements in the fields of radiomics, radiogenomics, and machine learning have prompted numerous studies exploring multiple directions for the prediction of IDH1 mutation status in gliomas through non-invasive methods. The gene discussed is IDH1; the disease is central nervous system cancer.